GW expects full-year profit on earlier German launch plans for Sativex
This article was originally published in Scrip
Executive Summary
GW Pharmaceuticals says it now expects to record a full-year profit as opposed to a small loss as launch plans in Germany for its cannabis-based multiple sclerosis-related spasticity treatment Sativex "are progressing faster than anticipated" by its marketing partner Almirall.